BioSpace News Archive

C-suite

Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.

April 28, 2026

·

4 min read

·

Nick Paul Taylor

Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.

Earnings

Novartis’ sales dip as generics pressure intensifies, radioequivalents loom

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

April 28, 2026

·

2 min read

·

Tristan Manalac

Venture capital

Big Pharma–backed Coultreon bags $125M series A to unlock alternative immune pathway

Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.

April 28, 2026

·

2 min read

·

Tristan Manalac

man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top

Pancreatic cancer

Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up

Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.

April 28, 2026

·

3 min read

·

Tristan Manalac

The path to precision. The road to the center of the target. The concept of goal achievement, precision, strategic direction, and focus on results. Polygonal design, blue background.

Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

April 28, 2026

·

2 min read

·

Gabrielle Masson

Crossed fingers and polygraph. Dishonesy, fake news, manipulation concept. Vector illustration.

Regulatory

FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drug’s pivotal study in order to make it look effective.

April 28, 2026

·

2 min read

·

Tristan Manalac

Panoramic view of San Diego skyline with clear blue sky and calm ocean waters.

Cancer

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ Trodelvy showed promising results, while a complex combination by Agenus and MiNK Therapeutics failed to elicit an overall response.

April 28, 2026

·

5 min read

·

Andrea Park

Strategy for company development concept. Employees conduct comparative analysis to improve their work. Competitiveness of business. Cartoon flat vector illustration isolated on blue background

Obesity

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.

April 28, 2026

·

2 min read

·

Heather McKenzie

Mergers & acquisitions

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral pan-KRAS inhibitor KST-6051 in solid tumors.

April 28, 2026

·

1 min read

·

Annalee Armstrong

Press Releases

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development

April 28, 2026

·

5 min read